Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel


Angelergues A., Bellmunt J., Efstathiou E., Gonzalez I., Gyftaki R., Delanoy N., et al.

European Cancer Congress / 18th Meeting of the European-Cancer-Organization (ECCO) / 40th Meeting of the European-Society-for-Medical-Oncology (ESMO), Vienna, Avusturya, 25 - 29 Eylül 2015, cilt.51